American Association for Cancer Research
Browse

Supplemental Table 6 from Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts

Download (18.74 kB)
journal contribution
posted on 2023-08-09, 14:00 authored by Joanne Kotsopoulos, Cassandra A. Hathaway, Steven A. Narod, Lauren R. Teras, Alpa V. Patel, Chunling Hu, Siddhartha Yadav, Fergus J. Couch, Shelley S. Tworoger

Supplemental Table 6: Total number of mutations across 12 cancer predisposing genes among ovarian cancer cases and controls in the NHS, NHSII, and CPSII

History

ARTICLE ABSTRACT

With the widespread use of multigene panel genetic testing, population-based studies are necessary to accurately assess penetrance in unselected individuals. We evaluated the prevalence of germline pathogenic or likely pathogenic variants (mutations) in 12 cancer-predisposition genes and associations with ovarian cancer risk in three population-based prospective studies [Nurses’ Health Study (NHS), NHSII, Cancer Prevention Study II]. We included women with epithelial ovarian or peritoneal cancer (n = 776) and controls who were alive and had at least one intact ovary at the time of the matched case diagnosis (n = 1,509). Germline DNA was sequenced for mutations in 12 genes. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for ovarian cancer risk by mutation status. The mutation frequency across all 12 genes was 11.2% in cases and 3.3% in controls (P < 0.0001). BRCA1 and BRCA2 were the most frequently mutated (3.5% and 3.8% of cases and 0.3% and 0.5% of controls, respectively) and were associated with increased ovarian cancer risk [OR, BRCA1 = 12.38; 95% confidence interval (CI) = 4.72–32.45; OR, BRCA2 = 9.18; 95% CI = 3.98–21.15]. Mutation frequencies for the other genes were ≤1.0% and only PALB2 was significantly associated with risk (OR = 5.79; 95% CI = 1.09–30.83). There was no difference in survival for women with a BRCA germline mutation versus no mutation. Further research is needed to better understand the role of other mutations in ovarian cancer among unselected populations. Our data support guidelines for germline genetic testing for BRCA1 and BRCA2 among women diagnosed with epithelial ovarian cancer; testing for PALB2 may be warranted.

Usage metrics

    Cancer Epidemiology, Biomarkers & Prevention

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC